Training and Continuing Education
FDA Continuing Education Programs on Medscape
As part of a collaboration between FDA and Medscape , a series of Continuing Education activities are available to communicate important safety information to clinicians. Featuring FDA experts, these CME/CE certified courses cover a range of topics related to FDA's multi-faceted mission of protecting and promoting the public health by ensuring the safety and quality of medical products such as drugs, foods, and medical devices.
The complete terms and framework of the partnership with Medscape are described in the Memorandum of Understanding.
Continuing Education Programs
The Bad Ad Program and Prescription Drug Promotion
The goal of this activity is to educate healthcare professionals and students about the role they can play in helping the FDA ensure that prescription drug advertising and promotion is truthful and not misleading.
Tell It to the FDA: The Adverse Drug Event Case Report http://www.medscape.org/viewarticle/773104
Featuring Melissa M. Truffa, BSPharm, Associate Director, Division of Pharmacovigilance, FDA Office of Surveillance and Epidemiology, and Anna Fine, PharmD, Director, Health Professional Liaison Program, FDA Office of Special Health Issues. Learn how to prepare a relevant narrative to describe the adverse event in your case report for the FDA’s MedWatch system.
Your Patient Has an Adverse Reaction to a Drug: How to Report to FDA's MedWatch
Featuring Anna Fine, PharmD, Director, Health Professional Liaison Program, FDA Office of Special Health Issues. Learn how to identify the types of adverse events and product problems or errors that should be reported to FDA.
REMS Program for the Transmucosal Immediate-Release Fentanyl Products
Panel discussion featuring Theresa A. Toigo, RPh, MBA (Associate Director, Drug Safety Operations, FDA) and Sharon Hertz, MD (Deputy Director, Division of Anesthesia, Analgesia, and Addiction Products, FDA).
This CME/CE activity will explain why a risk evaluation and mitigation strategy (REMS) is needed to ensure safe and effective use of the transmucosal immediate-release fentanyl products.
Risk Evaluation and Mitigation Strategies: An Introduction for Physicians, Nurses, and Pharmacists
Panel discussion moderated by Claudia Karwoski, PharmD, Director, Division of Risk Management, FDA Center for Drug Evaluation and Research. This CME/CE activity addresses the use of risk evaluation and mitigation strategies, an important and evolving topic that has wide-reaching implications for physicians, nurses, and pharmacists.
Transforming a Clinician Into an Investigator: What Does It Take?
Panel discussion moderated by Dr. Leonard Sacks, Acting Director, Office of Critical Path Programs at FDA. This CME/CE activity will help clarify the responsibilities of clinical investigators and address some of the challenges that investigators face today.
| || |